Kurzfassung

Efficacy and safety Pegylated-Proline-Interferon-Alpha 2B (AOP2014) in maintaining deep molecular remissions in patients with chronic myeloid leukemia (CML) who discontinue ABL-kinase inhibitor therapy - a randomized phase II, multicenter trial with post-study follow-up